10 results
EFFICACY OBJECTIVESThe primary efficacy objective for this study is to evaluate the efficacy of lebrikizumabused as adjunctive therapy with TCS compared with TCS in patients with persistentmoderate to severe AD, as measured by Eczema Area and…
PRIMARY OBJECTIVES * To evaluate the efficacy of lebrikizumab compared with placebo as measured by theability of patients to achieve lower daily doses of OCS while maintaining control oftheir asthma* To evaluate periostin as a predictive biomarker…
To evaluate the effect of intranasal esketamine 84 mg on cognition, and duration of cognitive effects (if present), as assessed using a computerized test battery (Cogstate®).
To compare the effect of amiloride on lithium-induced Nephrogenic Diabetes Insipidus with the effect of hydrochlorothiazide, measured as urine volume and maximal urine osmolality.
Primary Objective:In this pilot study, the authors aim is to investigate whether esketamine reduces the incidence of POD in elderly patientspresenting for noncardiac surgery.Secondary Objective(s):To examine whether esketamine has an effect on the…
Primary objective: to investigate the effect of amiloride on urine volume and urinary concentrating ability in patients on chronic lithium therapy suffering from polyuria.We hypothesize that amiloride therapy will improve urinary concentating…
To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16
Objective 1: To determine the effects of S-ketamine on brain activation in healthy women, healthy women prone to depression and fibromyalgia patients.Objective 2: To determine the effects of S-ketamine on mood and other depression-related behavioral…
We aim to investigate if arterial stiffness is exacerbated due to a high-salt diet in patients with ADPKD. We also intend to explore whether treatment with amiloride prevents the effect of high salt on arterial stiffness.
Primary Objectives* To investigate the effects of PO and IV S-ketamine and its metabolite S-norketamine on functional CNS tests up to 6h (acute effects) and 24h (delayed effects) after administration using NeuroCart test battery in healthy subjects…